Checkpoint Inhibitors for Non-Small Cell Lung Cancer
Study Investigating Anti-drug Antibodies in NSCLC Patients Exposed to Checkpoint Inhibitors (IMB)
Recruiting
Observational Study
NSCLC
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 270 (estimated)
- Sponsor
- Fondazione Ricerca Traslazionale · Other
Who this trial is looking for
This trial is looking for adults with non-small cell lung cancer (NSCLC) who are candidates for certain cancer treatments called checkpoint inhibitors. Participants will need to provide blood samples and give consent to join the study.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with non-small cell lung cancer.
- I can provide blood samples.
- I am 18 years or older.
- I agree to follow the trial procedures.
- I have a performance status of 0-2.
- I am a candidate for a therapy with a checkpoint inhibitor.
- I have given written informed consent.
You may not be able to join if
- I cannot provide blood samples.
- I have had previous therapy with any checkpoint inhibitor.
- I am a candidate for therapy with a checkpoint inhibitor combined with chemotherapy.
- I am pregnant.
- I am breastfeeding.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Non-small cell lung cancer (NSCLC) is one of the leading causes of death in Western countries. Today, a new frontier in the fight against cancer is immunotherapy, a treatment that aims to "awaken" the patient's immune system to help it recognize and attack cancer cells.
Among the various approaches, there is significant focus on therapies that activate T lymphocytes, a type of immune cell, encour…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically or cytologically confirmed diagnosis of NSCLC
* Possibility to obtain blood samples
* Patient candidate, in any therapy line, for a therapy with any checkpoint inhibitor including single agent pembrolizumab, single agent atezolizumab, single agent nivolumab, sin…
Contacts